Neurotoxicity Syndromes Clinical Trial
Official title:
Scopolamine Treatment for Patients With Organophosphate Poisoning - a Randomized, Double Blind, Placebo-Controlled Study.
Organophosphate (OP) compounds are a major threat as chemical warfare agents or in terrorist
act. OPs are also the active ingredient of many insecticides. Ingestion of insecticides is a
common cause of death among people who commit suicide in developing countries. OPs poisoning
also frequently occurs after accidental exposure to agricultural OPs and in children as a
result of unintentional ingestion.
The use of competitive inhibitors of acetylcholine other than atropine for patient with
organophosphate (OP) poisoning is controversial. Because scopolamines' ability to cross the
blood brain barrier is better than atropine, it has been suggested that scopolamine should
be used OP poisoned patients who have central nervous system (CNS) manifestations. However
there is controversy regarding its potential benefit in the treatment of organophosphate
poisoning in humans. To the best of our knowledge there are no randomised controlled studies
on the use of scopolamine in humans. This prospective randomised controlled study is aimed
to determine whether adding scopolamine to the standard treatment of atropine and oximes in
patients with CNS symptoms of OP poisoning improve the outcome.
Objective: to determine whether adding scopolamine to the standard treatment of atropine and oximes improve the outcome of patients with OP poisoning and CNS manifestations. Design: A multi-center, randomized, double blind, placebo controlled study. Setting: Emergency Departments & Intensive Care Units in Israel. Participants: Patients 2 -60 years old with acute OP poisoning and CNS manifestations. Interventions: In addition to standard treatment with atropine and obidoxime, eligible patients will be randomly assigned to one of two treatment groups, scopolamine group, and placebo group (both given in the same volume). Scopolamine will be given IM or IV in a dose of 0.25mg for adults and 0.006mg/kg for children every 4 hours. At least three doses of scopolamine (or placebo) will be given. The medical staff will be blinded to the treatment given. Main outcome measures: Improvement in neurological status, duration of seizures and number of days on ventilator. Data analysis: The main outcome measures, will be compared using the Student's t-test or the Mann-Whitney tests as appropriate. The *2 or Fisher Exact tests, as appropriate, will be used for comparisons of categorical variables. We will use multiple logistic regression to examine the extent to which variables predict success or failure of the treatment. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
Terminated |
NCT03954106 -
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
|
Phase 2 | |
Active, not recruiting |
NCT02481336 -
To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity
|
||
Terminated |
NCT00176553 -
A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity
|
N/A |